The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

ConclusionsVidofludimus demonstrated a positive safety profile, making it a promising candidate for the treatment of a variety of immune-related diseases.Trial RegistrationsClinicalTrials.gov identifier: NCT01010581.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research